Merus (NASDAQ:MRUS) Receives $85.92 Average Target Price from Brokerages

Merus (NASDAQ:MRUS) has been given an average rating of “Buy” by the sixteen analysts that are covering the company, Marketbeat.com reports. Fourteen analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $85.92.

MRUS has been the subject of several research reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $85.00 target price on shares of Merus in a research note on Monday, December 9th. Piper Sandler initiated coverage on Merus in a research note on Thursday, February 13th. They issued an “overweight” rating and a $84.00 target price for the company. Wells Fargo & Company assumed coverage on Merus in a research note on Friday, February 7th. They set an “overweight” rating and a $91.00 price objective for the company. Citigroup increased their price objective on Merus from $89.00 to $97.00 and gave the company a “buy” rating in a research note on Monday, December 9th. Finally, HC Wainwright reissued a “buy” rating and set a $85.00 price objective on shares of Merus in a research note on Monday, December 2nd.

Merus Price Performance

Shares of MRUS opened at $47.37 on Friday. The firm has a market cap of $3.24 billion, a P/E ratio of -11.99 and a beta of 1.11. The stock has a 50 day simple moving average of $41.72 and a two-hundred day simple moving average of $46.93. Merus has a 1 year low of $37.77 and a 1 year high of $61.61.

Hedge Funds Weigh In On Merus

Institutional investors have recently added to or reduced their stakes in the company. State of Wyoming bought a new position in Merus in the fourth quarter worth $48,000. Wells Fargo & Company MN increased its holdings in Merus by 27.3% in the 4th quarter. Wells Fargo & Company MN now owns 1,400 shares of the biotechnology company’s stock worth $59,000 after buying an additional 300 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in Merus in the 4th quarter worth about $60,000. nVerses Capital LLC boosted its position in Merus by 750.0% in the third quarter. nVerses Capital LLC now owns 1,700 shares of the biotechnology company’s stock worth $85,000 after purchasing an additional 1,500 shares during the last quarter. Finally, Avior Wealth Management LLC purchased a new position in Merus in the fourth quarter worth about $76,000. Institutional investors own 96.14% of the company’s stock.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.